

Ref: EPL/CS/SE/0014/2025

Date: February 07, 2025

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Regulatory Order(s)**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby submit the disclosure regarding an Order received by Emcure Pharmaceuticals Limited's subsidiary, Zuventus Healthcare Limited ("Zuventus"), for the Financial Year 2017-18, from the Office of the Deputy Commissioner of CGST & Central Excise Division-I, Lucknow, on February 06, 2025.

The relevant details as required pursuant to Regulation 30 and Part A of Schedule III of Listing Regulations are provided in "**Annexure A**", enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

**Chetan Sharma**  
Company Secretary & Compliance Officer  
Membership Number: F8352

## Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

**Annexure-A**

**Disclosure under Para A of Part A of Schedule III to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Information</b>
1	Name of the Authority	Office of the Deputy Commissioner of CGST & Central Excise , Division-I, Lucknow
2	Nature and details of the action(s) taken, initiated or order(s) passed	Section 74 of Central Goods and Services Tax Act, 2017
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	February 06, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	The Company has received an order confirming demand for tax, interest and penalty: (i) Tax amounting to Rs. 61,32,694/- (ii) Applicable interest thereon and (iii) Penalty to the tune of Rs. 61,32,694/-
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	There is no material impact on the Holding Company's financial, operation or other activities. Zuventus will take the necessary action and file an appeal against this order.

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251